A Seismic Shift in the Treatment of Chronic Lymphocytic Leukemia

Bruce Cheson, MD


February 08, 2022

In reflecting on the narrow range of treatment options available to his first patient, such as chlorambucil and vincristine, and later, combination therapies such as bendamustine-rituximab, Bruce Cheson, MD, characterizes the jump from chemotherapy-based courses to more recent, targeted regimens composed of Bruton's tyrosine kinase (BTK) inhibitors, such as ibrutinib, and monoclonal antibodies, such as obinutuzumab, as a "seismic revolution" — a tectonic shift that allows a wider latitude for patients in terms of treatment approaches, resulting in more positive outcomes.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.